Opening Ceremony at SOLACI-CACI 2017 Congress

The largest Interventional Cardiology Congress in Latin America has already started. At Pacífico Room, Hilton Buenos Aires Hotel, the Scientific and Organizing Committee presented the objectives and contents for the next three intense days of scientific activity.

Opening Ceremony at SOLACI-CACI 2017 Congress
The first Congress activity was an international joint session with TCT.

The first Congress session was an international joint session with TCT.

 

Congress President Dr. Ruben Piraino highlighted the registration record of over 3000 attendees from all over the world. He also mentioned the 450 faculty members (425 from Latin America and 25 international guests) involved in the event and the 10 live cases, the 8 edited cases, round tables, lunch symposiums, and more, as the main attractions in this “unforgettable event.”

 

Dr. Fernando Cura and Dr. Alberto Sampaolesi (from the Scientific Committee) talked about a “need for a different kind of event, given the disparateness within the scientific audience, composed by both novice professionals and true experts in the field.” They also emphasized the crucial support received from the industry, without which no event of this magnitude could have been pulled off. Furthermore, they expressed their hope that “this work will result in growth for this specialty in this geographical region, higher benefits for patients, and, above all, an increase in the quality of cardiovascular health.”

 

SOLACI President Dr. Ricardo Lluberas mentioned that “the work carried out by the Scientific and Organizing Committee throughout this year was absolutely self-sacrificing. In consequence, once this Congress is over and we return to our homes, we will surely bring with us satisfaction derived from the fact that SOLACI-CACI 2017 will have effectively contributed to the strengthening of interventional cardiology in Latin America.”


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Check out the best images of the El Salvador 2024 Sessions

Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....